For investors looking to join solid fundamental momentum with positive technical patterns, a multi-layered screening method can be very useful. One approach is to search for stocks that show a high-growth earnings profile, are in a verified uptrend, and are now pausing in a way that indicates a possible breakout. This method relies on three specific ChartMill scores: the High Growth Momentum (HGM) Rating, which measures short-term earnings speed and analyst outlook; the Technical Rating (TA), which assesses the general condition and direction of a stock; and the Setup Rating, which finds the strength of a current pause pattern. A stock performing strongly in all three areas may offer an interesting chance where solid fundamentals are meeting a positive chart formation.
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) appears as a candidate from this type of screen, showing the traits that growth and momentum investors frequently look for.
Fundamental Growth Momentum
Arcutis, a commercial-stage biotech company working on skin treatments, shows the high growth path that is the center of the HGM Rating system. This rating combines information on earnings and sales growth, speed, profit margins, earnings surprises, and analyst changes. ARQT’s latest financial results display several of these important traits:
- Notable Revenue Growth: The company’s top-line increase is substantial, with Trailing Twelve Month (TTM) revenue growth above 129%. Importantly, recent three-month sales growth has been very high, with the last reported quarter showing year-over-year growth of over 121%.
- Fast EPS Improvement: While the company is not yet regularly profitable on a net income basis, the direction in earnings per share is strongly positive. The EPS growth rate over the past TTM period is almost 80%, and the growth sped up to 118% in the latest quarter compared to the year-ago period. This speed increase is a key element the HGM Rating aims to find.
- Regular Earnings Surprises: ARQT has surpassed analyst EPS estimates in all of the last four quarters, with an average surprise above 62%. This regular outperformance indicates management performance may be beating market expectations.
- Positive Analyst Changes: Supporting the momentum argument, analysts have grown more optimistic, increasing their average EPS estimate for the next fiscal year by over 15% in the last three months. Such upward changes often come before more positive price movement.
These elements lead to ARQT’s HGM Rating of 6, showing a good base of fundamental momentum that is key to the high-growth investment plan.
Technical Strength and Trend
Apart from fundamentals, a stock needs to be in a good technical state to benefit from its growth. Based on the detailed technical report, ARQT receives a solid Technical Rating of 8 out of 10. This score shows a strong and steady uptrend when considered with the wider market.
- Market Outperformance: The report states that ARQT is doing better than 93% of all stocks in the market over the past year and is a front-runner within its biotechnology industry group, doing better than 82% of similar companies. This relative strength is a sign of market-leading stocks.
- Set Uptrend: The long-term direction is labeled positive, with the stock trading well above its important rising moving averages (the 100-day and 200-day). It is now trading in the higher part of its 52-week range, which goes from $11.75 to $31.77.
- Pause Within Trend: While the long-term direction is up, the short-term direction is noted as neutral. This is not always a bad sign; it often means the stock is resting or pausing its recent gains, which is exactly what the Setup Rating examines.
Strong Setup Pattern
The last part is timing. A stock in a solid uptrend can be overbought and dangerous to buy. ARQT’s Setup Rating of 8 indicates it is in a positive pause stage, providing a possible entry point. The technical analysis summary points out that "prices have been consolidating lately and the volatility has been reduced."
- Set Trading Range: Over the past month, the stock has traded between about $24.50 and $27.62, forming a base.
- Clear Support and Resistance: The analysis finds a clear support area around $26.50 and a close resistance point at $27.32. A clear move above this resistance could show the restart of the upward trend.
- Useful Levels: The report proposes a possible trade setup with an entry point just above the $27.32 resistance (a buy-stop order) and a stop-loss set below the $26.06 support level. This gives a defined, rules-based method to handle the trade based on the chart formation.
Combination for the Momentum Investor
For an investor using this joined growth-and-setup plan, ARQT offers a situation where interesting fundamental momentum is meeting a technically good chart. The company’s speeding commercial launch, shown by large sales growth and regular earnings beats, gives the fundamental "drive." This is happening while the stock chart shows the wanted "coiling" action, a pause within a main uptrend, that often comes before a next move higher. The method is made to find stocks where these two factors meet, trying to join a move pushed by both earnings surprises and technical breakout forces.
Want to find other stocks that match this high-growth momentum breakout description? You can use the screen yourself with the High Growth Momentum Breakout Setups Screen on ChartMill.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any securities. The analysis is based on data provided and reflects the situation at the time of writing. Investing in stocks, particularly in biotechnology companies like Arcutis, involves substantial risk, including the potential loss of principal. Always conduct your own due diligence and consider consulting with a qualified financial advisor before making any investment decisions.
